Latest Breaking News On - வாஸ்குலர் ஆராய்ச்சி - Page 2 : comparemela.com
Going Against Guidelines—Nearly 50% of PAD Patients Do Not Receive Statin Therapy
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
Healthy fat impacted by change in diet and circadian clock, study finds
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Düsseldorf: Torsello leitet Gefäßchirurgie am Augusta-Krankenhaus
rp-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rp-online.de Daily Mail and Mail on Sunday newspapers.
Jan 1, 2021
But if rivaroxaban is ’in’, is DAPT ’out’?
The introduction of direct oral anticoagulants (DOACs) in 2010 significantly changed clinical algorithms for prevention of VTE and stroke, as well as management of atrial fibrillation. In this report, which was initially published March 29, 2020, researchers presented findings that support a role for rivaroxaban in revascularization procedures in patients with PAD. BreakingMED is republishing this report as part of its year end clinical review series.
Findings from a trial of more than 6,564 patients undergoing revascularization procedures for peripheral artery disease are likely to change clinical practice, signaling a death knell for dual antiplatelet therapy while boosting the use of direct oral anticoagulant (DOAC) therapy in these patients.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial .
ARCA biopharma, Inc.December 15, 2020 GMT
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines
rNAPc2 is the only novel compound being developed for COVID-19 Associated Coagulopathy
Topline trial data anticipated in the second quarter of 2021
Data from this development program will also inform potential development in additional RNA virus-associated diseases
ADVERTISEMENT
WESTMINSTER, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first patients have been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating